Mumbai's slums may be reaching herd immunity, study finds


Some of the largest slums in Mumbai, India, may be nearing herd coronavirus immunity, a new serological survey found, Bloomberg reports.
The study tested 6,936 people across three suburbs in Mumbai — Dahisar, Chembur, and Matunga — and discovered that 57 percent of the subjects had coronavirus antibodies, a figure far higher than the 21 percent found in New York City in April and 14 percent in Stockholm, Sweden, in May. Per Bloomberg, epidemiologists generally believe a population must reach infection levels of 60 percent to achieve herd immunity, so the study indicates the neighborhoods are pretty much there. The survey appears to go hand-in-hand with a steep decline in cases in the slums in recent weeks, despite India having the world's fastest growth in infections overall.
Social distancing is a challenge in the crowded Mumbai neighborhoods, which seemingly makes them well-suited for the virus' spread, and the study suggests that it did so widely. Fortunately, the population in the slums is young and more likely to avoid severe cases of COVID-19. That, coupled with successful government containment measures that helped catch cases early and ensure high quality care, have kept the fatality low in the slums, even if many infections went undetected, Bloomberg notes.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
It's encouraging that some of Mumbai's slums may be closing in on herd immunity without experiencing a high death rate, but the jury is still out on how long immunity lasts. It's also worth noting antibody rates were not nearly as high in other parts of Mumbai, where social distancing is more feasible. Read more at Bloomberg.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Confessions of a Brain Surgeon: an 'exceptional' documentary
The Week Recommends Retired neurosurgeon Henry Marsh reflects on his pioneering work with exquisitely 'raw honesty'
-
A new subtype of diabetes was found and it may require different treatment
Under the radar It is prevalent in Black Africans and Americans
-
Crossword: August 20, 2025
The Week's daily crossword
-
Texas declares end to measles outbreak
Speed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
RFK Jr. shuts down mRNA vaccine funding at agency
Speed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC